Morning movers: Atkore jumps 26.3% on $95 cash deal

Today's separate Morning Read covers futures, oil and the calendar. This brief stays with individual stocks and uses delayed pre-market quotes captured at 05:45 ET on 3 August 2026.

ATKR: +26.3% after Prysmian signs a $95 cash deal

Prysmian said it entered a definitive merger agreement to buy Atkore for $95 per share in cash, implying an enterprise value of about $3.8 billion. Both boards approved the transaction, and the companies target a close by the end of calendar 2026, subject to Atkore shareholder approval, regulatory clearance and customary conditions. This is a confirmed agreement, not the earlier weekend report.

The objective price references are the $72.96 prior close, the $80.60–$92.40 pre-market range and the $95 cash consideration. The strategic logic is cable plus cable-adjacent infrastructure: Atkore sells conduit, cable-management systems, framing and related products used in data centres, construction and utilities. Prysmian expects $150 million of annual run-rate EBITDA synergies within three years. The main risk is execution: a signed deal can still be delayed, repriced or terminated.

BMY +7.4%, AZN -6.0%: reported tie-up talks split the trade

CNBC and Reuters reported that AstraZeneca and Bristol Myers Squibb had held tie-up discussions, tracing the story to reporting by the Financial Times. CNBC said analysts were perplexed by the industrial logic. Neither company's current SEC filings or official press-release index showed a matching transaction announcement at our evidence cut, so this section remains explicitly reported and unconfirmed by the companies.

Why opposite directions? The tape may be assigning different financing, governance or strategic risks to each side, but the terms needed to test that explanation are absent. Peers can react to the possibility of large-pharma consolidation, yet no peer move confirms this particular deal. The only clean watch item is new primary evidence: a company statement, an SEC filing, a regulatory disclosure or an explicit denial.

Also on the radar

• KOS -3.0% at $2.61: Nasdaq listed a pre-market earnings event, but the official result package had not cleared the two-source file check; the sub-$5 price and the separate oil move keep it off the feature list.
• PLTR +2.7% at $126.42: results are scheduled after the close, already flagged in today's Morning Read. The binary event is the catalyst to verify later, not an earnings number that does not yet exist.
• SNAP -3.8% at $4.51: Nasdaq lists results after hours. The pending event, sub-$5 share price and lack of a separate confirmed morning catalyst make it radar-only.

What to watch today

• 09:30 ET: compare the opening auction with the delayed quote cut; regular-session liquidity can reset every pre-market gap.
• ATKR: watch the spread to the confirmed $95 cash offer and any merger filing that adds conditions, timing or termination terms.
• BMY and AZN: treat only company or regulatory disclosures as confirmation; headlines alone do not create deal terms.
• After the open: rebuild exact listed-option bid, ask, open interest and volume before any wheel analysis.
• After the close: use issuer releases for PLTR and SNAP rather than reacting to headline summaries.